This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • The efficacy and safety of liraglutide as adjunct ...
Clinical trial

The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, multinational, multi-centre trial

Read time: 1 mins
Last updated:3rd Jun 2013
To confirm the efficacy of liraglutide as adjunct to insulin treatment on glycaemic control, and to confirm the superiority of liraglutide treatment compared to placebo, both adjunct to insulin treatment, with regards to reduction in total daily insulin dose and body weight loss, after 52 weeks of treatment in subjects with established type 1 diabetes with inadequate glycaemic control.
Category Value
Study start date 2013-06-03

View full details